<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20298" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Deep Vein Thrombosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Waheed</surname>
            <given-names>Sheikh M.</given-names>
          </name>
          <aff>Punjab Institute of Cardiology</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kudaravalli</surname>
            <given-names>Pujitha</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hotwagner</surname>
            <given-names>David T.</given-names>
          </name>
          <aff>St Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sheikh Waheed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pujitha Kudaravalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Hotwagner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20298.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>A deep-vein thrombosis (DVT) is a blood clot that forms within the deep veins, usually of the leg, but can occur in the arms and the mesenteric and cerebral veins. Deep-vein thrombosis is a common and important disease. It is part of the venous thromboembolism disorders, representing the third most common cause of death from cardiovascular disease after heart attacks and stroke. Even in patients who do not get pulmonary emboli, recurrent thrombosis and "post-thrombotic syndrome" are major causes of morbidity. This activity reviews the etiology, presentation, evaluation, and management of deep vein thrombosis and reviews the role of the interprofessional team in evaluating, diagnosing, and managing the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Discuss the risk factors for developing deep vein thrombosis.</p></list-item><list-item><p>Describe the examination findings and evaluation process of a patient with suspected deep vein thrombosis, including indicated laboratory analysis.</p></list-item><list-item><p>Summarize the treatment and management strategies for deep vein thrombosis, including preventative measures.</p></list-item><list-item><p>Outline the evaluation and management of deep vein thrombosis and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20298&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20298">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20298.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Deep vein thrombosis (DVT) is an obstructive disease with a hindering venous reflux mechanism.<xref ref-type="bibr" rid="article-20298.r1">[1]</xref> DVT usually involves the lower limb venous system, with clot formation originating in a deep calf vein and propagating proximally.<xref ref-type="bibr" rid="article-20298.r2">[2]</xref>&#x000a0;See <bold>Image.</bold> Deep Vein Thrombosis. It is a common venous thromboembolic (VTE) disorder with an incidence of 1.6 per 1000 annually.<xref ref-type="bibr" rid="article-20298.r3">[3]</xref>&#x000a0;The rate of particular site involvement depends on the anatomical location as follows, distal veins 40%, popliteal 16%, femoral 20%, common femoral 20%, and iliac veins 4%.<xref ref-type="bibr" rid="article-20298.r4">[4]</xref></p>
        <p>A deep-vein thrombosis (DVT) is a blood clot that forms within the deep veins, usually of the leg, but can occur in the arms and the mesenteric and cerebral veins. Deep-vein thrombosis is a common and important disease. It is part of the venous thromboembolism disorders, representing the third most common cause of death from cardiovascular disease after heart attacks and stroke. Even in patients who do not get pulmonary emboli, recurrent thrombosis and "post-thrombotic syndrome"&#x000a0;are major causes of morbidity.<xref ref-type="bibr" rid="article-20298.r5">[5]</xref><xref ref-type="bibr" rid="article-20298.r6">[6]</xref><xref ref-type="bibr" rid="article-20298.r7">[7]</xref>&#x000a0;Deep-vein thrombosis is a major medical problem accounting for most cases of pulmonary embolism. Only through early diagnosis and treatment can the morbidity be reduced.</p>
      </sec>
      <sec id="article-20298.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Risk Factors</bold>
</p>
        <p>Following are the risk factors that are considered causes of deep venous thrombosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Reduced blood flow: Immobility (bed rest, general anesthesia, operations, stroke, long flights)<xref ref-type="bibr" rid="article-20298.r8">[8]</xref><xref ref-type="bibr" rid="article-20298.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Increased venous pressure: Mechanical compression or functional impairment leading to reduced flow in the veins (neoplasm, pregnancy, stenosis, or congenital anomaly which increases outflow resistance)<xref ref-type="bibr" rid="article-20298.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Mechanical injury to the vein: Trauma, surgery, peripherally inserted venous catheters, previous DVT, intravenous drug abuse&#x000a0;<xref ref-type="bibr" rid="article-20298.r11">[11]</xref><xref ref-type="bibr" rid="article-20298.r12">[12]</xref><xref ref-type="bibr" rid="article-20298.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Increased blood viscosity: Polycythaemia rubra vera, thrombocytosis, dehydration&#x000a0;<xref ref-type="bibr" rid="article-20298.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Anatomic variations in venous anatomy can contribute to thrombosis</p>
          </list-item>
        </list>
        <p>
<bold>Increased Risk of Coagulation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Genetic deficiencies: Anticoagulation proteins C and S, antithrombin III deficiency, factor V Leiden mutation&#x000a0;<xref ref-type="bibr" rid="article-20298.r14">[14]</xref><xref ref-type="bibr" rid="article-20298.r15">[15]</xref><xref ref-type="bibr" rid="article-20298.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Acquired:&#x000a0;Cancer, sepsis, myocardial infarction, heart failure, vasculitis, systemic lupus erythematosus and lupus anticoagulant, inflammatory bowel disease, nephrotic syndrome, burns, oral estrogens, smoking, hypertension, diabetes&#x000a0;<xref ref-type="bibr" rid="article-20298.r12">[12]</xref><xref ref-type="bibr" rid="article-20298.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Constitutional Factors</bold>
</p>
        <p>Obesity, pregnancy, the advanced age of older than 60, surgery, critical care admission, dehydration, and cancer are the established causalities of DVT and VTE.<xref ref-type="bibr" rid="article-20298.r18">[18]</xref><xref ref-type="bibr" rid="article-20298.r19">[19]</xref><xref ref-type="bibr" rid="article-20298.r20">[20]</xref><xref ref-type="bibr" rid="article-20298.r21">[21]</xref>&#x000a0;Obesity is associated with a hypercoagulability status via two mechanisms, 1. increased fibrinogen levels that may even surpass twofold the normal value, and 2. slower venous circulation flow in the infra diaphragmatic and especially in the lower limbs.<xref ref-type="bibr" rid="article-20298.r20">[20]</xref> Both factors, associated with disorders in several coagulation factors, favor the appearance of venous thrombosis, thrombophlebitis, and thromboembolic events, and mostly fatal pulmonary thromboembolisms (PE), which are the primary cause of mortality in obese patients.<xref ref-type="bibr" rid="article-20298.r20">[20]</xref></p>
        <p>Potential risk factors of deep vein thrombosis might be categorized according to the transient, persistent, or unprovoked criteria. Accordingly, transient risk factors are as follows: 1. surgery with general anesthetics, 2. hospitalization, 3. Cesarean section, 4. hormone replacement therapy, 5. pregnancy and peripartum period, 6. lower extremity injury with limited mobility for more than 72 hours.<xref ref-type="bibr" rid="article-20298.r4">[4]</xref>&#x000a0;It should be noted that general anesthesia for longer than 30 minutes and hospitalization for longer than 72 hours are considered the transient risk factors of DVT.<xref ref-type="bibr" rid="article-20298.r4">[4]</xref>&#x000a0;However, active cancers and specific medical conditions that increase the risk of venous thromboembolism are categorized as persistent risk factors. Systemic lupus erythematosus and inflammatory bowel disease are among the predisposing medical conditions.<xref ref-type="bibr" rid="article-20298.r4">[4]</xref></p>
        <p>Any further etiological risk factors not categorized among either transient or persistent subgroups should be labeled as unprovoked VTE.<xref ref-type="bibr" rid="article-20298.r4">[4]</xref><xref ref-type="bibr" rid="article-20298.r1">[1]</xref>&#x000a0;For instance, a recent cohort study, including 500 participants evaluating the association of blood lipid levels and lower extremity DVT (LEDVT), demonstrated that higher total cholesterol levels, high-density lipoprotein (HDL-C), and apolipoprotein A1 (ApoA1) were associated with a decreased risk of lower extremity DVT (LEDVT). However, higher triglyceride levels (TG) were associated with a greater risk of LEDVT.<xref ref-type="bibr" rid="article-20298.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20298.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Incidence and prevalence: Deep-vein thrombosis and pulmonary emboli are common and often "silent" and thus go undiagnosed or are only picked up at autopsy. Therefore, the incidence and prevalence are often underestimated. It is thought the annual incidence of DVT is 80 cases per 100,000, with a prevalence of lower limb DVT of 1 case per 1000 population.<xref ref-type="bibr" rid="article-20298.r1">[1]</xref> Annually in the United States, more than 200,000 people develop venous thrombosis; of those, 50,000 cases are complicated by pulmonary embolism.<xref ref-type="bibr" rid="article-20298.r22">[22]</xref><xref ref-type="bibr" rid="article-20298.r23">[23]</xref><xref ref-type="bibr" rid="article-20298.r24">[24]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Age: Deep-vein thrombosis is rare in children, and the risk increases with age, most occurring in the over-40&#x000a0;age group.<xref ref-type="bibr" rid="article-20298.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gender: There is no consensus about whether there is a sex bias in the incidence of DVT.&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ethnicity<bold>:</bold> There is evidence from the United States that there is an increased incidence of DVT and an increased risk of complications in African Americans and white people compared to Hispanic and Asian populations.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Associated diseases: In the hospital, the most commonly associated conditions are malignancy, congestive heart failure, obstructive airway disease, and patients undergoing surgery.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20298.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>According to the Virchow triad, the following are the main pathophysiological mechanisms involved in DVT:</p>
        <list list-type="bullet">
          <list-item>
            <p>Damage to the vessel wall</p>
          </list-item>
          <list-item>
            <p>Blood flow turbulence</p>
          </list-item>
          <list-item>
            <p>Hypercoagulability</p>
          </list-item>
        </list>
        <p>Thrombosis is a protective mechanism that prevents the loss of blood and seals off damaged blood vessels. Fibrinolysis counteracts or stabilizes thrombosis. The triggers of venous thrombosis are frequently multifactorial, with the different parts of the triad of Virchow contributing in varying degrees in each patient, but all result in early thrombus interaction with the endothelium. This stimulates local cytokine production and causes leukocyte adhesion to the&#x000a0;endothelium, promoting venous thrombosis. Depending on the relative balance between the coagulation and thrombolytic pathways, thrombus propagation occurs. DVT is commonest in the lower limb below the knee and starts at low-flow sites, such as the soleal sinuses, behind venous valve pockets.<xref ref-type="bibr" rid="article-20298.r25">[25]</xref><xref ref-type="bibr" rid="article-20298.r26">[26]</xref><xref ref-type="bibr" rid="article-20298.r27">[27]</xref>&#x000a0;A potential correlation between DVT and atherosclerosis (AS) has been proposed.<xref ref-type="bibr" rid="article-20298.r1">[1]</xref>&#x000a0;The endothelial dysfunction involved in the pathophysiological mechanism of DVT would potentially result in AS. Accordingly, a greater risk of subsequent AS in patients with DVT is predicted.<xref ref-type="bibr" rid="article-20298.r1">[1]</xref></p>
      </sec>
      <sec id="article-20298.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In the venous system following acute thrombosis formation, an extensive remodeling process occurs. Neutrophils and macrophages infiltrate the fibrin clot from within the lumen of the vessel over weeks leading to cytokine release and, eventually, fibroblast and collagen replacement of fibrin. This remodeling and fibrosis can result in diminished blood flow long after the acute thrombosis resolves.<xref ref-type="bibr" rid="article-20298.r28">[28]</xref></p>
      </sec>
      <sec id="article-20298.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of acute lower extremity DVT varies with the anatomic distribution, extent, and degree of occlusion of the thrombus. Symptoms may range from absence to massive swelling and cyanosis with impending venous gangrene. Three patterns of thrombosis are usually recognized: isolated calf vein (distal), femoropopliteal, and iliofemoral thrombosis, and symptoms tend to be more severe as thrombosis extends more proximally (see <bold>Video.</bold> Popliteal Deep Vein Thrombosis With Partial Color Flow, Video). However, up to 50% of patients with acute DVT may lack specific signs or symptoms.&#x000a0;<xref ref-type="bibr" rid="article-20298.r5">[5]</xref><xref ref-type="bibr" rid="article-20298.r6">[6]</xref>&#x000a0;Postoperative patients are, in particular, more likely to have small, asymptomatic, distal, non-occlusive thrombi. When present, signs and symptoms of acute lower extremity DVT may include pain, edema, erythema, tenderness, fever, prominent superficial veins, pain with passive dorsiflexion of the foot (Homan&#x02019;s sign), and peripheral cyanosis. Phlegmasia cerulea dolens, characterized by the triad of massive swelling, cyanosis, and pain, is the most severe form of acute lower extremity DVT and results from complete thrombosis of an extremity&#x02019;s venous outflow.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045251/#b7-vsi-32-077">7</ext-link>] In advanced cases, it is marked by severe venous hypertension with collateral and microvascular thrombosis, leading to venous gangrene. Venous gangrene is particularly associated with warfarin-mediated protein C depletion in patients with cancer or heparin-induced thrombocytopenia.<xref ref-type="bibr" rid="article-20298.r8">[8]</xref><xref ref-type="bibr" rid="article-20298.r9">[9]</xref></p>
        <p>Obtaining the diagnosis of DVT only based on clinical signs and symptoms is notoriously inaccurate. The signs and symptoms of DVT are generally non-specific. They may be associated and misdiagnosed with other lower extremity disorders. Accordingly, lymphedema, superficial venous thrombosis, and cellulitis should be excluded. However, the most common presenting symptoms with inconsistent sensitivity and specificity are calf pain and swelling. The former index has a sensitivity of 75% to 91% and a specificity of 3% to 87%, and the latter might have a sensitivity of up to 97% and a specificity of up to 88%.<xref ref-type="bibr" rid="article-20298.r29">[29]</xref>&#x000a0;None of the signs or symptoms is sufficiently sensitive or specific, either alone or in combination, to accurately diagnose or exclude thrombosis.<xref ref-type="bibr" rid="article-20298.r30">[30]</xref></p>
        <p>
<bold>History</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pain (50% of patients)</p>
          </list-item>
          <list-item>
            <p>Redness</p>
          </list-item>
          <list-item>
            <p>Swelling (70% of patients)</p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Limb edema (may be unilateral or bilateral if the thrombus extends to pelvic veins)</p>
          </list-item>
          <list-item>
            <p>Red and hot skin with dilated veins</p>
          </list-item>
          <list-item>
            <p>Tenderness</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20298.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The following veins are categorized as deep veins according to the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification: 1. inferior vena cava, 2. common iliac, 3. internal and external iliac, 4. pelvic veins, including a. gonadal, and b. broad ligament veins, 5.&#x000a0;common femoral, 6.&#x000a0;deep femoral vein, 7. femoral, 8. popliteal, 9. paired crural veins of anterior and posterior tibial and peroneal, 10. muscular veins of&#x000a0;gastrocnemial, and soleal.<xref ref-type="bibr" rid="article-20298.r31">[31]</xref>&#x000a0;</p>
        <p>As per the National Institute for Clinical Excellence guidelines following investigations are done:</p>
        <list list-type="bullet">
          <list-item>
            <p>D-dimers (very&#x000a0;sensitive but not very&#x000a0;specific)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coagulation profile</p>
          </list-item>
          <list-item>
            <p>Proximal leg vein ultrasound, which, when positive, indicates that the patient should be treated as having a DVT</p>
          </list-item>
        </list>
        <p>Deciding how to investigate is determined by the risk of DVT. The first step is to assess the clinical probability of a DVT using the Wells scoring system.</p>
        <list list-type="bullet">
          <list-item>
            <p>The clinical probability is low for patients with a score of 0 to 1, but for those with two or above, the clinical probability is high.</p>
          </list-item>
          <list-item>
            <p>If a patient scores 2 or above, either a proximal leg vein ultrasound scan should be done within 4 hours, and if the result is negative, a D-dimer test should be&#x000a0;done. If imaging is not possible within 4 hours, a D-dimer test should be undertaken, and an interim 24-hour dose of a parenteral anticoagulant should be given. A proximal leg vein ultrasound scan should be carried out within 24 hours of being requested.</p>
          </list-item>
          <list-item>
            <p>In the case of a positive D-dimer test and a negative proximal leg vein ultrasound scan, the proximal leg vein ultrasound scan should be repeated 6 to 8 days later for all patients.</p>
          </list-item>
          <list-item>
            <p>If the patient does not score 2 on the DVT Wells score, but the D-dimer test is positive, the patient should have a proximal leg vein ultrasound scan within 4 hours, or&#x000a0;if this is not possible, the patient should receive an interim 24-hour dose of a parenteral anticoagulant. A&#x000a0;proximal leg vein ultrasound scan should be carried out within 24 hours of being requested.</p>
          </list-item>
          <list-item>
            <p>In all patients diagnosed with DVT, treat as if there is a positive proximal leg vein ultrasound scan.<xref ref-type="bibr" rid="article-20298.r32">[32]</xref><xref ref-type="bibr" rid="article-20298.r33">[33]</xref><xref ref-type="bibr" rid="article-20298.r34">[34]</xref></p>
          </list-item>
        </list>
        <p>Clinical decision rules such as the&#x000a0;Pulmonary Embolism Rule-Out Criteria (PERC)&#x000a0;and the Wells Criteria should be employed with the patient presenting with a possible DVT. Risk stratification is crucial in deciding diagnostic and management options. Patients who meet PERC criteria may need no further testing, whereas those who do not meet PERC criteria and are low probability based on the Wells criteria may be candidates for rule-out with a D-dimer. The D-dimer test is sensitive but not specific and should be used selectively in a low-probability patient who does not have other confounding diagnoses that could produce a false positive test. The test&#x000a0;also&#x000a0;should&#x000a0;be used with caution, perhaps with different cut-off values in the elderly.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470381/">[5]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470381/">[6]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470381/">[7]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470381/">[8]</ext-link></p>
        <p>Imaging modalities available to evaluate for DVT include diagnostic ultrasound, vascular studies, CT venograms, and point-of-care ultrasound (POCUS). The POCUS exam is described below. Rapid diagnosis or rule-out by the emergency provider can expedite necessary treatment and reduce the length of stay, and it is particularly useful when access to 24-hour ultrasound is unavailable. There is evidence that emergency practitioners can perform a two-point compression exam at the two highest probability sites for identifying a DVT: femoral and popliteal veins. However, recent literature suggests a 2-region approach where clinicians do serial compression testing may significantly improve diagnostic sensitivity without greatly increasing diagnostic time. This point-of-care ultrasound exam should be used with other clinical decision rules and is perhaps most useful in those patients with high and low pre-test probability.</p>
        <p>With the patient supine in the frog-leg position, apply approximately 20 to 30 degrees of reverse Trendelenburg to increase venous distention. Place the high-frequency linear transducer (5 to 10 MHz) in the transverse plane at the anatomical location of the inguinal ligament. Just distal to the inguinal ligament, the common femoral vein can be visualized. Apply direct pressure to the vein. The complete collapse of the vein indicates there is no presence of a DVT. Continue distally along the femoral vein to where the greater saphenous vein and deep femoral vein deviate from the common femoral vein. Complete compression of all venous structures at these levels rules out a proximal DVT.</p>
        <p>Next, proceed to the popliteal region. Laterally rotate the leg, flex the knee, and place the high-frequency transducer transversely in the popliteal fossa. The popliteal vein typically resides just anterior to the popliteal artery. Apply a compressive force once again and observe for complete compression. Compress the areas just proximal and distal to the popliteal fossa as well to complete the two-region technique. If DVT studies are negative, repeat testing may be required in one to two weeks to rule out a propagating calf DVT further. Alternatively, sending a D-dimer test may be adequate in certain patient populations. Typical laboratory tests&#x000a0;also&#x000a0;should be sent to evaluate for coagulation status, blood count, and renal function.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470381/">[9]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK470381/">[10]</ext-link><xref ref-type="bibr" rid="article-20298.r35">[35]</xref></p>
      </sec>
      <sec id="article-20298.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of DVT aims to prevent pulmonary embolism, reduce morbidity, and prevent or minimize the risk of developing&#x000a0;post-thrombotic syndrome. The cornerstone of treatment is anticoagulation. NICE guidelines only recommend treating proximal DVT (not distal) and those with pulmonary emboli. In each patient, the risks of anticoagulation need to be weighed against the benefits.<xref ref-type="bibr" rid="article-20298.r36">[36]</xref><xref ref-type="bibr" rid="article-20298.r37">[37]</xref><xref ref-type="bibr" rid="article-20298.r38">[38]</xref>&#x000a0;Treatment for DVT should be addressed mainly according to the underlying causality of DVT as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The preferred anticoagulant to address DVT in cancer-associated thromboembolism is low molecular weight heparin and factor Xa inhibitors, including&#x000a0;rivaroxaban.<xref ref-type="bibr" rid="article-20298.r39">[39]</xref>&#x000a0;However, in the following circumstances, the higher levels of anticoagulation should be considered: 1. recently diagnosed cancer, 2. extensive VTE circumstances, and 3. cancer treatment-related adverse effects, including vomiting.<xref ref-type="bibr" rid="article-20298.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p>In circumstances where once-daily oral therapy is the preferred management, the following options are viable; 1. rivaroxaban, 2. edoxaban, and 3. vitamin-K antagonist (VKA)</p>
          </list-item>
          <list-item>
            <p>In the context of liver disease, DVT should be managed with low-molecular-weight heparin.<xref ref-type="bibr" rid="article-20298.r41">[41]</xref>&#x000a0;Direct oral anticoagulants (DOACs) are contraindicated in raised INR levels.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with renal disease suppressed creatinine clearance to less than 30 ml/min, VKAs are recommended. DOACs and LMWH should be avoided in patients with end-stage renal disease.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with a remarkable past medical history of coronary artery disease, the following alternatives are recommended: 1. VKA, 2. rivaroxaban, 3. apixaban, and 4. edoxaban.<xref ref-type="bibr" rid="article-20298.r42">[42]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with remarkable dyspepsia or any past medical history suggestive of gastrointestinal bleeding, VKA, and apixaban are the preferred treatments. It should be noted that DOCAs, eg, dabigatran, factor Xa inhibitors, eg, rivaroxaban, and selective factor Xa inhibitors, eg, edoxaban, might be associated with higher rates of gastrointestinal bleeding.<xref ref-type="bibr" rid="article-20298.r43">[43]</xref><xref ref-type="bibr" rid="article-20298.r44">[44]</xref><xref ref-type="bibr" rid="article-20298.r45">[45]</xref></p>
          </list-item>
          <list-item>
            <p>In the group of patients with a history compatible with poor compliance, VKA is preferred. However, it should be noted that some patients might still be highly compliant with other alternatives, including DOACs.<xref ref-type="bibr" rid="article-20298.r46">[46]</xref></p>
          </list-item>
          <list-item>
            <p>If thrombolytic therapy is indicated, unfractionated heparin is indicated.<xref ref-type="bibr" rid="article-20298.r47">[47]</xref></p>
          </list-item>
          <list-item>
            <p>In patients who might later be subjected to reversal of thrombolytic therapy, it should be noted that reversal agents for DOACs are not universally available.</p>
          </list-item>
          <list-item>
            <p>Since most anticoagulants have the potential to cross the placenta, the preferred anticoagulation therapy during pregnancy is LMWH.</p>
          </list-item>
        </list>
        <p>Moreover, the following guidelines address the required duration of treatment.</p>
        <list list-type="bullet">
          <list-item>
            <p>Prescribe low-molecular-weight heparin or fondaparinux for 5 days or until the international normalized ratio (INR)&#x000a0;is&#x000a0;greater than 2 for 24 hours (unfractionated heparin for patients with renal failure and increased risk of bleeding).</p>
          </list-item>
          <list-item>
            <p>Supplement with vitamin K antagonists for 3 months.</p>
          </list-item>
          <list-item>
            <p>In patients with cancer, consider anticoagulation for 6 months with low-molecular-weight heparin.</p>
          </list-item>
          <list-item>
            <p>In patients with unprovoked DVT, consider vitamin K antagonists&#x000a0;beyond 3 months.</p>
          </list-item>
          <list-item>
            <p>Rivaroxaban is an oral factor Xa inhibitor that has recently been approved by the Food and Drug Administration and NICE and is attractive because there is no need for regular INR monitoring.</p>
          </list-item>
          <list-item>
            <p>If the platelet count drops to less than 75,000, switch from heparin to fondaparinux, which is not associated with heparin-induced thrombocytopenia.</p>
          </list-item>
        </list>
        <p>Thrombolysis:&#x000a0;The indications for the use of thrombolytics include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptomatic iliofemoral DVT</p>
          </list-item>
          <list-item>
            <p>Symptoms of less than 14 days duration&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Good functional status</p>
          </list-item>
          <list-item>
            <p>A life expectancy of 1 year or more&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Low risk of bleeding</p>
          </list-item>
        </list>
        <p>The use of thrombolytic therapy can result in an intracranial bleed, and hence, careful patient selection is vital. Recently endovascular interventions like catheter-directed extraction, stenting, or mechanical thrombectomy have been tried with moderate success.</p>
        <list list-type="bullet">
          <list-item>
            <p>Compression hosiery: Below-knee graduated compression stockings with an ankle pressure greater than 23 mm Hg for 2 years if there are no contraindications</p>
          </list-item>
          <list-item>
            <p>Inferior vena cava filters: If anticoagulation is contraindicated or if emboli are occurring despite adequate anticoagulation</p>
          </list-item>
        </list>
        <p>
<bold>Newer Drugs</bold>
</p>
        <p>Rivaroxaban, apixaban, dabigatran, edoxaban, and betrixaban are relatively newer factor Xa inhibitors approved for prophylaxis of deep vein thrombosis. The duration of DVT treatment is 3&#x000a0;to 6 months, but recurrent episodes may require at least 12 months of treatment. Patients with cancer need long-term treatment. Inferior vena cava filters are not recommended in acute DVT. There are both permanent and temporary inferior vena cava filters available. These devices may decrease the rate of recurrent DVT but do not affect survival. Today, only patients with contraindications to anticoagulation with an increased risk of bleeding should have these filters inserted.</p>
      </sec>
      <sec id="article-20298.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The following are differential diagnoses of deep venous thrombosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cellulitis</p>
          </list-item>
          <list-item>
            <p>Post-thrombotic syndrome (especially venous eczema and lipodermatosclerosis)</p>
          </list-item>
          <list-item>
            <p>Ruptured Baker cyst</p>
          </list-item>
          <list-item>
            <p>Trauma</p>
          </list-item>
          <list-item>
            <p>Superficial thrombophlebitis</p>
          </list-item>
          <list-item>
            <p>Peripheral edema, heart failure, cirrhosis, nephrotic syndrome</p>
          </list-item>
          <list-item>
            <p>Venous or lymphatic obstruction</p>
          </list-item>
          <list-item>
            <p>Arteriovenous fistula and congenital vascular abnormalities</p>
          </list-item>
          <list-item>
            <p>Vasculitis&#x000a0;<xref ref-type="bibr" rid="article-20298.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20298.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Given the increased risk of thromboembolism, patients with clinically active malignancy would benefit from thromboprophylaxis. A meta-analysis looking at a total of 33 trials and 11,972 patients provided more evidence that thromboprophylaxis decreased the incidence of VTE in cancer patients who were undergoing chemotherapy or surgery, with no apparent increase in the incidence of significant bleeding.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[7]</ext-link>&#x000a0;Current guidelines from the National Comprehensive Cancer Network (NCCN) recommend anticoagulation with unfractionated heparin or low molecular weight heparin in hospitalized cancer patients as thromboprophylaxis. Mechanical prophylaxis should be used instead of anticoagulation therapy in patients experiencing active bleeding, thrombocytopenia (platelet count below 50,000/MCL), evidence of hemorrhagic coagulopathy, or having an indwelling neuraxial catheter. Contraindications to mechanical prophylaxis include acute deep venous thrombosis and severe arterial insufficiency.</p>
        <p>A recent meta-analysis addressed the question of the optimum duration of anticoagulation in cancer patients hospitalized with acute illnesses. This study looked at trials comparing standard-duration versus extended-duration anticoagulation prophylaxis. The risk of VTE was not significantly lower in the extended-duration prophylaxis group of patients, but the risk of bleeding was about 2-fold higher.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[8]</ext-link>&#x000a0;Regarding outpatient VTE prophylaxis, surgical pelvic or abdominal oncology patients would benefit from continuing VTE prophylaxis up to four weeks post-operation. The use of aspirin or anticoagulation therapy for patients with multiple myeloma on immunomodulatory medications is recommended based on risk stratification with the IMPEDE VTE score.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[9]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[10]</ext-link>&#x000a0;For patients with solid cancers on chemotherapy and high Khorana score, prophylactic anticoagulation with direct oral anticoagulation or low molecular weight heparin showed a decrease in the incidence of pulmonary embolism.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[11]</ext-link></p>
        <p>Low molecular weight heparin (LMWH) remains the preferred anticoagulation option for managing cancer-associated thrombosis.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[12]</ext-link>&#x000a0;The dosage recommendation for LMWH is 1 mg/kg every 12 hours and 1 mg/kg once daily for patients with creatinine clearance of less than 30 mL/minute. Avoid the use of LMWH in patients on dialysis. Other treatment options include direct oral anticoagulants like apixaban, rivaroxaban, edoxaban, fondaparinux, and warfarin. In the Caravaggio trial, researchers found apixaban to be non-inferior to LMWH in treating cancer-associated VTE without an increased risk of significant bleeding.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[13]</ext-link></p>
        <p>Thrombolytic therapy can be used in patients with life or limb-threatening pulmonary embolism or acute deep vein thrombosis considering contraindications such as intracranial tumors or metastasis, active bleeding, and a history of intracranial hemorrhage. NCCN recommends a treatment duration minimum of 3 months or for the duration of active malignancy. For patients with non-catheter-related deep venous thrombosis or pulmonary embolism, indefinite anticoagulation is the recommendation.</p>
        <p>Continuing to assess for benefits vs. risks, as well as monitoring for complications, is essential. In patients with DVT located in the inferior vena cava, iliac, femoral, and popliteal veins, in addition to a contraindication to therapeutic anticoagulation, placement of retrievable vena cava filters can prevent pulmonary embolism. Once placed, it is important to periodically assess patients for resolution of contraindications, removal of the vena cava filters, and switching to therapeutic anticoagulation. For patients with catheter-associated thrombosis, treatment consists of removing the catheter or anticoagulation if the catheter remains.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK562222/">[10]</ext-link>&#x000a0;</p>
      </sec>
      <sec id="article-20298.s12" sec-type="Staging">
        <title>Staging</title>
        <p>The severity of the disease is classified as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Provoked: Due to acquired states (surgery, oral contraceptives, trauma, immobility, obesity, cancer)</p>
          </list-item>
          <list-item>
            <p>Unprovoked: Due to idiopathic or endogenous reasons; more likely to suffer recurrence if anticoagulation is discontinued</p>
          </list-item>
          <list-item>
            <p>Proximal:&#x000a0;Above the knee, affecting the femoral or iliofemoral veins; much more likely to lead to complications such as pulmonary emboli</p>
          </list-item>
          <list-item>
            <p>Distal:&#x000a0;Below the knee</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20298.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for DVT includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Many DVTs will resolve with no complications.</p>
          </list-item>
          <list-item>
            <p>Post-thrombotic syndrome occurs in 43% of patients 2 years post-DVT (30% mild, 10% moderate, and severe 3%).</p>
          </list-item>
          <list-item>
            <p>The risk of recurrence of DVT is high (up to 25%).</p>
          </list-item>
          <list-item>
            <p>Death occurs in approximately 6% of DVT cases and 12% of pulmonary embolism cases within one month of diagnosis.</p>
          </list-item>
          <list-item>
            <p>Early mortality after venous thromboembolism is strongly associated with the presentation of pulmonary embolism, advanced age, cancer, and underlying cardiovascular disease.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20298.s14" sec-type="Complications">
        <title>Complications</title>
        <p>The following are the 2 major complications of DVT:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary emboli (paradoxical emboli if an atrial-septal defect is present)</p>
          </list-item>
          <list-item>
            <p>Post-thrombotic syndrome</p>
          </list-item>
          <list-item>
            <p>Bleeding from the use of anticoagulants</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20298.s15" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Thromboprophylaxis strategies for hospitalized patients at potential risk for deep vein thrombosis include pharmacological and mechanical arms. In the pharmacological aspect,&#x000a0; unfractionated and low-molecular-weight heparins, novel oral anticoagulants (NOACs), such as direct thrombin binders, including dabigatran, factor Xa direct binders, including rivaroxaban, and aspirin or warfarin should be considered.<xref ref-type="bibr" rid="article-20298.r20">[20]</xref><xref ref-type="bibr" rid="article-20298.r48">[48]</xref><xref ref-type="bibr" rid="article-20298.r49">[49]</xref>&#x000a0;It should be noted that the results from network meta-analysis indicate that NOACs are an effective treatment for thromboprophylaxis of VTE or VTE-related mortality) in the extended treatment scenarios. However, the complication with bleeding risk differs. Accordingly, apixaban was reported to have the most favorable profile. The comparison was published in the context of other NOACs, warfarin with endpoints of INR 2.0&#x000a0;to 3.0, and aspirin.<xref ref-type="bibr" rid="article-20298.r49">[49]</xref><xref ref-type="bibr" rid="article-20298.r50">[50]</xref><xref ref-type="bibr" rid="article-20298.r51">[51]</xref></p>
        <p>In the mechanical prophylactic arm, the following measures should be evaluated;</p>
        <list list-type="bullet">
          <list-item>
            <p>Graduated compression stockings</p>
          </list-item>
          <list-item>
            <p>Intermittent pneumatic compression devices</p>
          </list-item>
          <list-item>
            <p>Venous foot pumps</p>
          </list-item>
          <list-item>
            <p>Electrical stimulation devices</p>
          </list-item>
        </list>
        <p>Still, mechanical devices should be applied in conjunction with pharmacological prophylaxis.<xref ref-type="bibr" rid="article-20298.r20">[20]</xref></p>
      </sec>
      <sec id="article-20298.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated on the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ambulation</p>
          </list-item>
          <list-item>
            <p>Wearing compression stockings</p>
          </list-item>
          <list-item>
            <p>Discontinuing smoking</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20298.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Deep-vein thromboses can occur in many settings and almost every medical specialty; failing to diagnose DVT can result in a pulmonary embolus, which can be fatal. DVTs also result in more prolonged admission to the hospital and drug treatment that can last 3&#x000a0;to 9 months, all of which add to the cost of healthcare. Thus its diagnosis and management are best made with an interprofessional healthcare team consisting of clinicians, specialists, nurses, physical therapists, vascular technicians, and pharmacists.</p>
        <p>The focus is on the&#x000a0;prevention of DVT.&#x000a0;In addition to clinicians, both nurses and pharmacists are vital in educating patients about DVT prophylaxis. Nurses are the first professionals to encounter patients being admitted to the hospital,&#x000a0;and it is here that the prevention of DVT starts. Nurses must educate the patients on the importance of ambulation, complying with compression stockings, and taking the prescribed anticoagulation medications. In both the operating room and post-surgery, nurses play a key role in reminding physicians of the need for DVT prophylaxis. Each hospital has guidelines on DVT prophylaxis and treatment, and all healthcare workers should follow them.</p>
        <p>Once a DVT has developed, the pharmacist should be familiar with the current anticoagulants and their indications. They can consult with the prescribing/ordering clinician and perform medication reconciliation. Plus, the pharmacist must educate the patients on the need for treatment compliance and the need to undergo regular testing to ensure that the INR is therapeutic.<xref ref-type="bibr" rid="article-20298.r37">[37]</xref><xref ref-type="bibr" rid="article-20298.r52">[52]</xref>&#x000a0;Once DVT is diagnosed, the treatment is with an anticoagulant for 3&#x000a0;to 6 months, and again, monitoring of the INR by a hematology nurse or pharmacist is necessary. Further, these patients need to be monitored for bleeding. Open communication between the interprofessional team is the only way to treat DVT and lower the morbidity of the drugs safely.</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Nearly 300,000 patients die from a pulmonary&#x000a0;embolus yearly in the US alone. Despite countless guidelines and education of healthcare workers, DVT prophylaxis is often not done. The fact is that DVT is preventable in the majority of patients, and the onus is on healthcare workers to be aware of the condition. For those who develop a DVT and survive, post-thrombotic&#x000a0;phlebitis is a lifelong sequela with no ideal treatment.<xref ref-type="bibr" rid="article-20298.r53">[53]</xref><xref ref-type="bibr" rid="article-20298.r54">[54]</xref>&#x000a0;This is why interprofessional care coordination and open communication is crucial to managing these patients long-term.&#x000a0;</p>
      </sec>
      <sec id="article-20298.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20298&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20298">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/deep-vein-thrombosis-dvt/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20298">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20298/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20298">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20298.s19">
        <fig id="article-20298.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Deep Vein Thrombosis. This illustration compares normal blood flow with that of deep vein thrombosis and embolism within the deep veins of the leg. Contributed by M Schick, DO</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dvt__femoral__and__saphenous__with__partial__flow-2-2.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-20298.s20">
        <fig id="article-20298.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Deep Vein Thrombosis. This illustration compares normal blood flow with that of deep vein thrombosis and embolism within the deep veins of the leg. (https://creativecommons.org/licenses/by-nd/2.0/deed.en)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DVT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20298.s21">
        <title>References</title>
        <ref id="article-20298.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Association Between Blood Lipid Levels and Lower Extremity Deep Venous Thrombosis: A Population-Based Cohort Study.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>28</volume>
            <fpage>10760296221121282</fpage>
            <pub-id pub-id-type="pmid">36189865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Stent patency rates and prognostic factors of endovascular intervention for iliofemoral vein occlusion in post-thrombotic syndrome.</article-title>
            <source>BMC Surg</source>
            <year>2022</year>
            <month>Jul</month>
            <day>12</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>269</fpage>
            <pub-id pub-id-type="pmid">35831845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albricker</surname>
                <given-names>ACL</given-names>
              </name>
              <name>
                <surname>Freire</surname>
                <given-names>CMV</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>SND</given-names>
              </name>
              <name>
                <surname>Alcantara</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Saleh</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Cantisano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Teodoro</surname>
                <given-names>JAR</given-names>
              </name>
              <name>
                <surname>Porto</surname>
                <given-names>CLL</given-names>
              </name>
              <name>
                <surname>Amaral</surname>
                <given-names>SID</given-names>
              </name>
              <name>
                <surname>Veloso</surname>
                <given-names>OCG</given-names>
              </name>
              <name>
                <surname>Petisco</surname>
                <given-names>ACGP</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>MVL</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sobreira</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Moraes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verrastro</surname>
                <given-names>CGY</given-names>
              </name>
              <name>
                <surname>Man&#x000e7;ano</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>RSL</given-names>
              </name>
              <name>
                <surname>Muglia</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Matushita</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>AMN</given-names>
              </name>
              <name>
                <surname>Pianta</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>AASMDD</given-names>
              </name>
              <name>
                <surname>Naves</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>MLC</given-names>
              </name>
              <name>
                <surname>Rochitte</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Joint Guideline on Venous Thromboembolism - 2022.</article-title>
            <source>Arq Bras Cardiol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>797</fpage>
            <page-range>797-857</page-range>
            <pub-id pub-id-type="pmid">35508060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stubbs</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mouyis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Deep vein thrombosis.</article-title>
            <source>BMJ</source>
            <year>2018</year>
            <month>Feb</month>
            <day>22</day>
            <volume>360</volume>
            <fpage>k351</fpage>
            <pub-id pub-id-type="pmid">29472180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thachil</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The use of direct oral anticoagulants in chronic kidney disease.</article-title>
            <source>Br J Haematol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>183</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-184</page-range>
            <pub-id pub-id-type="pmid">30183070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naringrekar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>It's Not All Deep Vein Thrombosis: Sonography of the Painful Lower Extremity With Multimodality Correlation.</article-title>
            <source>J Ultrasound Med</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>1075</fpage>
            <page-range>1075-1089</page-range>
            <pub-id pub-id-type="pmid">30171620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seifi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dengler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Godoy</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary embolism in severe traumatic brain injury.</article-title>
            <source>J Clin Neurosci</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>57</volume>
            <fpage>46</fpage>
            <page-range>46-50</page-range>
            <pub-id pub-id-type="pmid">30154000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belcaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornelli</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Dugall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hosoi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cotellese</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feragalli</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol&#x000ae; supplementation (LONFLIT Registry Study).</article-title>
            <source>Minerva Cardioangiol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-159</page-range>
            <pub-id pub-id-type="pmid">29512362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Bed rest versus early ambulation with standard anticoagulation in the management of deep vein thrombosis: a meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>e0121388</fpage>
            <pub-id pub-id-type="pmid">25860350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lensing</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Brighton</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rehm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trajanovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Beyer-Westendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pap</surname>
                <given-names>&#x000c1;F</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Prandoni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.</article-title>
            <source>Lancet Haematol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>e37</fpage>
            <page-range>e37-46</page-range>
            <pub-id pub-id-type="pmid">27030066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruskin</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Deep vein thrombosis and venous thromboembolism in trauma.</article-title>
            <source>Curr Opin Anaesthesiol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-218</page-range>
            <pub-id pub-id-type="pmid">29334497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mechanick</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Apovian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brethauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Joffe</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Lindquist</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pessah-Pollack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Urman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cleek</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Figaro</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Kothari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seger</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Still</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &#x00026; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists.</article-title>
            <source>Surg Obes Relat Dis</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-247</page-range>
            <pub-id pub-id-type="pmid">31917200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vay&#x000e1;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suescun</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hemorheological parameters as independent predictors of venous thromboembolism.</article-title>
            <source>Clin Hemorheol Microcirc</source>
            <year>2013</year>
            <volume>53</volume>
            <issue>1-2</issue>
            <fpage>131</fpage>
            <page-range>131-41</page-range>
            <pub-id pub-id-type="pmid">22954636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Senst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tadi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Basit</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Hypercoagulability</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30855839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wypasek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Undas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Protein C and protein S deficiency - practical diagnostic issues.</article-title>
            <source>Adv Clin Exp Med</source>
            <year>2013</year>
            <season>Jul-Aug</season>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-67</page-range>
            <pub-id pub-id-type="pmid">23986205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Niikura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwakura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kurosaka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thrombin-antithrombin III complex tests.</article-title>
            <source>J Orthop Surg (Hong Kong)</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>170840616684501</fpage>
            <pub-id pub-id-type="pmid">28418276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ogata</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tsunoda</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.</article-title>
            <source>Clin Rheumatol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>4457</fpage>
            <page-range>4457-4471</page-range>
            <pub-id pub-id-type="pmid">34554329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Lacerda</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Dos Santos</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>De Jes&#x000fa;s</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>De Jes&#x000fa;s</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Leatherwood</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bermas</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Challenging cases in rheumatic pregnancies.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>57</volume>
            <issue>suppl_5</issue>
            <fpage>v18</fpage>
            <page-range>v18-v25</page-range>
            <pub-id pub-id-type="pmid">30137591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmaier</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ambesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Campia</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Venous Thromboembolism and Cancer.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>20</day>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>89</fpage>
            <pub-id pub-id-type="pmid">30128839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goktay</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Senturk</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Endovascular Treatment of Thrombosis and Embolism.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>906</volume>
            <fpage>195</fpage>
            <page-range>195-213</page-range>
            <pub-id pub-id-type="pmid">27664152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Risk factors and treatment of venous thromboembolism in perioperative patients with ovarian cancer in China.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>97</volume>
            <issue>31</issue>
            <fpage>e11754</fpage>
            <pub-id pub-id-type="pmid">30075594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Juul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>Hvas</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Low risk of venous thromboembolism following early pregnancy loss in pregnancies conceived by IVF.</article-title>
            <source>Hum Reprod</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1968</fpage>
            <page-range>1968-1972</page-range>
            <pub-id pub-id-type="pmid">30137318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharif</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eventov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kearon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parpia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sneath</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fuentes</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Marriott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the age-adjusted and clinical probability-adjusted D-dimer to exclude pulmonary embolism in the ED.</article-title>
            <source>Am J Emerg Med</source>
            <year>2019</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>845</fpage>
            <page-range>845-850</page-range>
            <pub-id pub-id-type="pmid">30077494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delluc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Mao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tromeur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chambry</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rault-Nagel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bressollette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mottier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Couturaud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lacut</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Incidence of upper-extremity deep vein thrombosis in western France: a community-based study.</article-title>
            <source>Haematologica</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>e29</fpage>
            <page-range>e29-e31</page-range>
            <pub-id pub-id-type="pmid">30076179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Piazza</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?</article-title>
            <source>Vasc Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>388</fpage>
            <page-range>388-399</page-range>
            <pub-id pub-id-type="pmid">30045685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Comparative study on deep venous thrombosis onset in hospitalized patients with different underlying diseases].</article-title>
            <source>Zhonghua Nei Ke Za Zhi</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>429</fpage>
            <page-range>429-434</page-range>
            <pub-id pub-id-type="pmid">29925128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budnik</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brill</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immune Factors in Deep Vein Thrombosis Initiation.</article-title>
            <source>Trends Immunol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>610</fpage>
            <page-range>610-623</page-range>
            <pub-id pub-id-type="pmid">29776849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ashorobi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ameer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Thrombosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">30860701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Thrombosis Complications in Pediatric Acute Lymphoblastic Leukemia: Risk Factors, Management, and Prevention: Is There Any Role for Pharmacologic Prophylaxis?</article-title>
            <source>Front Pediatr</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>828702</fpage>
            <pub-id pub-id-type="pmid">35359904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Joh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>UJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines.</article-title>
            <source>Vasc Specialist Int</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>77</fpage>
            <page-range>77-104</page-range>
            <pub-id pub-id-type="pmid">27699156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lurie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Passman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meisner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dalsing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Blebea</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carpentier</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>De Maeseneer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gasparis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Labropoulos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marston</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Rafetto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shortell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Uhl</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Urbanek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Rij</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eklof</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gloviczki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kistner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moneta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Padberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The 2020 update of the CEAP classification system and reporting standards.</article-title>
            <source>J Vasc Surg Venous Lymphat Disord</source>
            <year>2020</year>
            <month>May</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>342</fpage>
            <page-range>342-352</page-range>
            <pub-id pub-id-type="pmid">32113854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weick</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Dirschl</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Luu</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.</article-title>
            <source>J Am Acad Orthop Surg</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>26</volume>
            <issue>19</issue>
            <fpage>698</fpage>
            <page-range>698-705</page-range>
            <pub-id pub-id-type="pmid">30153117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denny</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Musale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edlin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Serracino-Inglott</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thachil</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chronic deep vein thrombosis.</article-title>
            <source>Acute Med</source>
            <year>2018</year>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>144</fpage>
            <page-range>144-147</page-range>
            <pub-id pub-id-type="pmid">30129947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahaghi</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Minhas</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Heresi</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism: New Imaging Tools and Modalities.</article-title>
            <source>Clin Chest Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>493</fpage>
            <page-range>493-504</page-range>
            <pub-id pub-id-type="pmid">30122174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Schick</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pacifico</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Deep Venous Thrombosis of the Lower Extremity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29262179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Altshuler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient.</article-title>
            <source>J Intensive Care Med</source>
            <year>2019</year>
            <season>Nov-Dec</season>
            <volume>34</volume>
            <issue>11-12</issue>
            <fpage>877</fpage>
            <page-range>877-888</page-range>
            <pub-id pub-id-type="pmid">30165770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>The effect of a multidisciplinary team on the implementation rates of major diagnostic and therapeutic procedures of chronic thromboembolic pulmonary hypertension.</article-title>
            <source>Heart Lung</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">30115494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ten Cate</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Secondary prophylaxis decision-making in venous thromboembolism: interviews on clinical practice in thirteen countries.</article-title>
            <source>Res Pract Thromb Haemost</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-48</page-range>
            <pub-id pub-id-type="pmid">30046672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thirlwall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lokare</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>MacCallum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kakkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>FDR</given-names>
              </name>
              <name>
                <surname>Petrou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Poole</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Maraveyas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Jul</month>
            <day>10</day>
            <volume>36</volume>
            <issue>20</issue>
            <fpage>2017</fpage>
            <page-range>2017-2023</page-range>
            <pub-id pub-id-type="pmid">29746227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boon</surname>
                <given-names>GJAM</given-names>
              </name>
              <name>
                <surname>Van Dam</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Klok</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Huisman</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Management and treatment of deep vein thrombosis in special populations.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>685</fpage>
            <page-range>685-695</page-range>
            <pub-id pub-id-type="pmid">30016119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Regal</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.</article-title>
            <source>Ann Pharmacother</source>
            <year>2016</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>402</fpage>
            <page-range>402-9</page-range>
            <pub-id pub-id-type="pmid">26861989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kruger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Douketis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hankey</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Deep vein thrombosis: update on diagnosis and management.</article-title>
            <source>Med J Aust</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>210</volume>
            <issue>11</issue>
            <fpage>516</fpage>
            <page-range>516-524</page-range>
            <pub-id pub-id-type="pmid">31155730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Padda</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <chapter-title>Edoxaban</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">33351434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Key</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Khorana</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kuderer</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bohlke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AYY</given-names>
              </name>
              <name>
                <surname>Arcelus</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Balaban</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Gates</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Kakkar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Liebman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Tempero</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Falanga</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-520</page-range>
            <pub-id pub-id-type="pmid">31381464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>KSH</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Risk of Postcolonoscopy Thromboembolic Events: A&#x000a0;Real-World Cohort Study.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>3051</fpage>
            <page-range>3051-3059.e4</page-range>
            <pub-id pub-id-type="pmid">36167228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.</article-title>
            <source>World J Gastroenterol</source>
            <year>2017</year>
            <month>Mar</month>
            <day>21</day>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1954</fpage>
            <page-range>1954-1963</page-range>
            <pub-id pub-id-type="pmid">28373761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nepal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kharel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhagat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ka Shing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ariel Coghlan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poudyal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ojha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sunder Shrestha</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta-analysis.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>145</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-23</page-range>
            <pub-id pub-id-type="pmid">34287841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Phatak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tushabe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Batson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>e0144856</fpage>
            <pub-id pub-id-type="pmid">26716830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horblyuk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Batson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>e0160064</fpage>
            <pub-id pub-id-type="pmid">27487187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rollins</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kanaan</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.</article-title>
            <source>Clin Ther</source>
            <year>2014</year>
            <month>Oct</month>
            <day>01</day>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1454</fpage>
            <page-range>1454-64.e3</page-range>
            <pub-id pub-id-type="pmid">25092394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almutairi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gellad</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Slack</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lo-Ciganic</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.</article-title>
            <source>Clin Ther</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>1456</fpage>
            <page-range>1456-1478.e36</page-range>
            <pub-id pub-id-type="pmid">28668628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Root</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Dudzinski</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Zakhary</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Sista</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary approach to the management of pulmonary embolism patients: the pulmonary embolism response team (PERT).</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>187</fpage>
            <page-range>187-195</page-range>
            <pub-id pub-id-type="pmid">29670358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCaughan</surname>
                <given-names>GJB</given-names>
              </name>
              <name>
                <surname>Favaloro</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Pasalic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Curnow</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation at the extremes of body weight: choices and dosing.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>817</fpage>
            <page-range>817-828</page-range>
            <pub-id pub-id-type="pmid">30148651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20298.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallaha</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Radha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of a new thromboprophylaxis regiment for total knee and total hip replacement: a retrospective cohort study in 265 patients.</article-title>
            <source>Patient Saf Surg</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">30123323</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
